|
1
|
Mohi MG and Neel BG: The role of Shp2
(PTPN11) in cancer. Curr Opin Genet Dev. 17:23–30. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
He RJ, Yu ZH, Zhang RY and Zhang ZY:
Protein tyrosine phosphatases as potential therapeutic targets.
Acta Pharmacol Sin. 35:1227–1246. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chan G, Kalaitzidis D and Neel BG: The
tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis
Rev. 27:179–192. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Matozaki T, Murata Y, Saito Y, Okazawa H
and Ohnishi H: Protein tyrosine phosphatase SHP-2: A proto-oncogene
product that promotes Ras activation. Cancer Sci. 100:1786–1793.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang W, Wang J, Moore DC, Liang H, Dooner
M, Wu Q, Terek R, Chen Q, Ehrlich MG, Quesenberry PJ and Neel BG:
Ptpn11 deletion in a novel progenitor causes metachondromatosis by
inducing hedgehog signalling. Nature. 499:491–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aceto N, Sausgruber N, Brinkhaus H,
Gaidatzis D, Martiny-Baron G, Mazzarol G, Confalonieri S, Quarto M,
Hu G, Balwierz PJ, et al: Tyrosine phosphatase SHP2 promotes breast
cancer progression and maintains tumor-initiating cells via
activation of key transcription factors and a positive feedback
signaling loop. Nat Med. 18:529–537. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhan Y, Counelis G and O'Rourke D: The
protein tyrosine phosphatase SHP-2 is required for EGFRvIII
oncogenic transformation in human glioblastoma cells. Exp Cell Res.
315:2343–2357. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang C, Hu F, Tai Y, Du J, Mao B, Yuan Z,
Wang Y and Wei L: The tumor suppressor role of Src homology
phosphotyrosine phosphatase 2 in hepatocellular carcinoma. J Cancer
Res Clin Oncol. 138:637–646. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tassidis H, Brokken LJ, Jirström K,
Bjartell A, Ulmert D, Härkönen P and Wingren AG: Low expression of
SHP-2 is associated with less favorable prostate cancer outcomes.
Tumor Biol. 34:637–642. 2013. View Article : Google Scholar
|
|
10
|
Yu SJ, Yu JK, Ge WT, Hu HG, Yuan Y and
Zheng S: SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are
prognosis-related in colorectal cancer. World J Gastroenterol.
17:2028–2036. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Han T, Xiang D-M, Sun W, Liu N, Sun HL,
Wen W, Shen WF, Wang RY, Chen C, Wang X, et al: PTPN11/Shp2
overexpression enhances liver cancer progression and predicts poor
prognosis of patients. J Hepatol. 63:651–660. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bard-Chapeau EA, Li S, Ding J, Zhang SS,
Zhu HH, Princen F, Fang DD, Han T, Bailly-Maitre B, Poli V, et al:
Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular
carcinogenesis. Cancer Cell. 19:629–639. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xiang D, Cheng Z, Liu H, Wang X, Han T,
Sun W, Li X, Yang W, Chen C, Xia M, et al: Shp2 promotes liver
cancer stem cell expansion by augmenting β-catenin signaling and
predicts chemotherapeutic response of patients. Hepatology.
65:1566–1580. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tsutsumi R, Masoudi M, Takahashi A, Fujii
Y, Hayashi T, Kikuchi I, Satou Y, Taira M and Hatakeyama M: YAP and
TAZ, hippo signaling targets, act as a rheostat for nuclear SHP2
function. Dev Cell. 26:658–665. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zheng H, Li S, Hsu P and Qu CK: Induction
of a tumor-associated activating mutation in protein tyrosine
phosphatase Ptpn11 (Shp2) Enhances mitochondrial metabolism,
leading to oxidative stress and senescence. J Biol Chem.
288:25727–25738. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hellmuth K, Grosskopf S, Lum CT, Würtele
M, Röder N, von Kries JP, Rosario M, Rademann J and Birchmeier W:
Specific inhibitors of the protein tyrosine phosphatase Shp2
identified by high-throughput docking. Proc Natl Acad Sci USA.
105:7275–7280. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zeng LF, Zhang RY, Yu ZH, Li S, Wu L,
Gunawan AM, Lane BS, Mali RS, Li X, Chan RJ, et al: Therapeutic
potential of targeting the oncogenic SHP2 phosphatase. J Med Chem.
57:6594–6609. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu W, Yu B, Xu G, Xu WR, Loh ML, Tang LD
and Qu CK: Identification of cryptotanshinone as an inhibitor of
oncogenic protein tyrosine phosphatase SHP2 (PTPN11). J Med Chem.
56:7212–7221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang X, He Y, Liu S, Yu Z, Jiang ZX, Yang
Z, Dong Y, Nabinger SC, Wu L, Gunawan AM, et al: Salicylic acid
based small molecule inhibitor for the oncogenic src homology-2
domain containing protein tyrosine phosphatase-2 (SHP2). J Med
Chem. 53:2482–2493. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen L, Pernazza D, Scott LM, Lawrence HR,
Ren Y, Luo Y, Wu X, Sung SS, Guida WC, Sebti SM, et al: Inhibition
of cellular Shp2 activity by a methyl ester analog of SPI-112.
Biochem Pharmacol. 80:801–810. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen L, Sung SS, Yip ML, Lawrence HR, Ren
Y, Guida WC, Sebti SM, Lawrence NJ and Wu J: Discovery of a novel
shp2 protein tyrosine phosphatase inhibitor. Mol Pharmacol.
70:562–570. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen YP, LaMarche MJ, Chan HM, Fekkes P,
Garcia-Fortanet J, Acker MG, Antonakos B, Chen CH, Chen Z, Cooke
VG, et al: Allosteric inhibition of SHP2 phosphatase inhibits
cancers driven by receptor tyrosine kinases. Nature. 535:148–152.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen C, Cao M, Zhu S, Wang C, Liang F, Yan
L and Luo D: Discovery of a novel inhibitor of the protein tyrosine
phosphatase Shp2. Sci Rep. 5:176262015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hartman ZR, Schaller MD and Agazie YM: The
tyrosine phosphatase SHP2 regulates focal adhesion kinase to
promote EGF-induced lamellipodia persistence and cell migration.
Mol Cancer Res. 11:651–664. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sausgruber N, Coissieux MM, Britschgi A,
Wyckoff J, Aceto N, Leroy C, Stadler MB, Voshol H, Bonenfant D and
Bentires-Alj M: Tyrosine phosphatase SHP2 increases cell motility
in triple-negative breast cancer through the activation of
SRC-family kinases. Oncogene. 34:2272–2278. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang RY, Yu ZH, Zeng L, Zhang S, Bai Y,
Miao J, Chen L, Xie J and Zhang ZY: SHP2 phosphatase as a novel
therapeutic target for melanoma treatment. Oncotarget.
7:73817–73829. 2016.PubMed/NCBI
|
|
27
|
Sieg DJ, Hauck CR, Ilic D, Klingbeil CK,
Schaefer E, Damsky CH and Schlaepfer DD: FAK integrates
growth-factor and integrin signals to promote cell migration. Nat
Cell Biol. 2:249–256. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang K, Zhao H, Ji Z, Zhang C, Zhou P,
Wang L, Chen Q, Wang J, Zhang P, Chen Z, et al: Shp2 promotes
metastasis of prostate cancer by attenuating the PAR3/PAR6/aPKC
polarity protein complex and enhancing epithelial-to-mesenchymal
transition. Oncogene. 35:1271–1282. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang FM, Liu HQ, Liu SR, Tang SP, Yang L
and Feng GS: SHP-2 promoting migration and metastasis of MCF-7 with
loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9
induced by IL-1β in vivo and in vitro. Breast Cancer Res Treat.
89:5–14. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Grossmann KS, Wende H, Paul FE, Cheret C,
Garratt AN, Zurborg S, Feinberg K, Besser D, Schulz H, Peles E, et
al: The tyrosine phosphatase Shp2 (PTPN11) directs
Neuregulin-1/ErbB signaling throughout Schwann cell development.
Proc Natl Acad Sci USA. 106:16704–16709. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang YS, Cheng CY, Chueh SH, Hueng DY,
Huang YF, Chu CM, Wu ST, Tai MC, Liang CM, Liao MH, et al:
Involvement of SHP2 in focal adhesion, migration and
differentiation of neural stem cells. Brain Dev. 34:674–684. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Inagaki K, Noguchi T, Matozaki T, Horikawa
T, Fukunaga K, Tsuda M, Ichihashi M and Kasuga M: Roles for the
protein tyrosine phosphatase SHP-2 in cytoskeletal organization,
cell adhesion and cell migration revealed by overexpression of a
dominant negative mutant. Oncogene. 19:75–84. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fujinaka Y, Matsuoka K, Iimori M, Tuul M,
Sakasai R, Yoshinaga K, Saeki H, Morita M, Kakeji Y, Gillespie DA,
et al: ATR-Chk1 signaling pathway and homologous recombinational
repair protect cells from 5-fluorouracil cytotoxicity. DNA Repair
(Amst). 11:247–258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tsang YH, Han X, Man WY, Lee N and Poon
RY: Novel functions of the phosphatase SHP2 in the DNA replication
and damage checkpoints. PLoS One. 7:e499432012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bradham C and McClay DR: p38 MAPK in
development and cancer. Cell Cycle. 5:824–828. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Koul HK, Pal M and Koul S: Role of p38 MAP
kinase signal transduction in solid tumors. Genes Cancer.
4:342–359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mamik MK and Ghorpade A: Src homology-2
domain-containing protein tyrosine phosphatase (SHP) 2 and p38
regulate the expression of chemokine CXCL8 in human astrocytes.
PLoS One. 7:e455962012. View Article : Google Scholar : PubMed/NCBI
|
